Targeted Therapeutics: Linking EGF Receptor Drugs to Diagnostics

Herceptin-HerceptTest is a successful model of the benefits of linking a therapeutic to a diagnostic test, but the ties aren't as clear-cut in the next crop of targeted therapies to come to market. EGF receptor-based drugs work on specific receptor targets in a variety of cancers, but scientists haven't been able so far to correlate patient response to the drugs to receptor presence or quantity. Yet the issue is extremely important, both to pharma companies seeking to determine how they will design their clinical trials and submit data to the FDA and to diagnostic companies looking for a new kind of market.

In an ideal world, the new group of targeted therapies making their way through clinical trials should follow the hugely successful Herceptin(trastuzumab)-HercepTest model—they should be utilized in subsets of patient populations, to be determined by a diagnostic that correlates well with therapeutic response rates. After all, targeted therapies are intended to act by modulating specific molecules or receptors and therefore ought to work on those patients who, at a minimum, have those molecules, or, as in the case of Herceptin, a Genentech Inc. drug for breast cancer, who have too much of the targeted receptor. (The HercepTest diagnostic kit is used to distinguish those who overexpress a particular protein, Her2/neu, from those who either express it in moderate levels or don't express it at all.) Indeed, in approving Herceptin, the FDA required it to be used in conjunction with a diagnostic—the first time the agency has ever made such a stipulation. FDA officials have indicated informally that they would like companies to incorporate diagnostics into other studies of targeted therapies to best determine which patients can benefit from these drugs. (See "Dako Ponders the Expanding Universe," IN VIVO, March 2000 [A#2000800040.)

But scientists aren't yet convinced of the best ways to use the current diagnostics in pre-selecting patients who are likely...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

Podcast: Acuitas CSO On CRISPR Delivery Breakthrough And Next-Gen Lipid Nanoparticle Technology

 
• By 

In Vivo sits down with Ying Tam, CSO at Acuitas Therapeutics, to discuss the company's role in delivering the first personalized CRISPR treatment to an infant and the clinical implications of new lipid nanoparticle technologies.

BioBytes: AI-Related Deals In Q2 ‘25

 
• By 

When it came to AI-related deals, the second quarter of 2025 was characterized by mostly modest financings.

Titans Of Pharma: Lilly’s Ricks Tops Big Pharma Pay Chart

 

The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.